IL204741A - Ceramide History for the Treatment of Multiple Cyst Diseases and Pharmaceuticals Containing These History - Google Patents

Ceramide History for the Treatment of Multiple Cyst Diseases and Pharmaceuticals Containing These History

Info

Publication number
IL204741A
IL204741A IL204741A IL20474110A IL204741A IL 204741 A IL204741 A IL 204741A IL 204741 A IL204741 A IL 204741A IL 20474110 A IL20474110 A IL 20474110A IL 204741 A IL204741 A IL 204741A
Authority
IL
Israel
Prior art keywords
derivatives
treatment
pharmaceutical compositions
kidney disease
polycystic kidney
Prior art date
Application number
IL204741A
Other languages
English (en)
Hebrew (he)
Other versions
IL204741A0 (en
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of IL204741A0 publication Critical patent/IL204741A0/en
Publication of IL204741A publication Critical patent/IL204741A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL204741A 2007-10-05 2010-03-25 Ceramide History for the Treatment of Multiple Cyst Diseases and Pharmaceuticals Containing These History IL204741A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99780307P 2007-10-05 2007-10-05
PCT/US2008/011450 WO2009045503A1 (en) 2007-10-05 2008-10-03 Method of treating polycystic kidney diseases with ceramide derivatives

Publications (2)

Publication Number Publication Date
IL204741A0 IL204741A0 (en) 2010-11-30
IL204741A true IL204741A (en) 2015-11-30

Family

ID=40108810

Family Applications (1)

Application Number Title Priority Date Filing Date
IL204741A IL204741A (en) 2007-10-05 2010-03-25 Ceramide History for the Treatment of Multiple Cyst Diseases and Pharmaceuticals Containing These History

Country Status (14)

Country Link
US (3) US8912177B2 (OSRAM)
EP (2) EP2550965B1 (OSRAM)
JP (3) JP5896601B2 (OSRAM)
KR (3) KR101640263B1 (OSRAM)
CN (2) CN101888840A (OSRAM)
AU (1) AU2008307516B2 (OSRAM)
BR (2) BRPI0817864A2 (OSRAM)
CA (1) CA2701649C (OSRAM)
ES (1) ES2660690T3 (OSRAM)
IL (1) IL204741A (OSRAM)
MX (2) MX2010003603A (OSRAM)
RU (2) RU2517345C9 (OSRAM)
SG (2) SG184721A1 (OSRAM)
WO (1) WO2009045503A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0517701A8 (pt) 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
ES2546181T3 (es) * 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
EP2594563B1 (en) * 2007-05-31 2018-07-18 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
CA2701649C (en) * 2007-10-05 2016-05-24 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
CN102271678B (zh) * 2008-10-03 2017-06-30 简詹姆公司 2‑酰胺基丙醇型葡糖神经酰胺合成酶抑制剂
WO2013059119A1 (en) * 2011-10-17 2013-04-25 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
BR112015003376A8 (pt) 2012-08-23 2018-01-23 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
WO2014150043A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
MX2016002199A (es) * 2013-08-21 2016-07-13 Alios Biopharma Inc Compuestos antivirales.
US9457016B2 (en) 2013-08-29 2016-10-04 New York University Methods for treating polycystic kidney disease
US10227323B2 (en) * 2013-09-20 2019-03-12 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
MX376685B (es) 2013-10-29 2025-03-07 Biomarin Pharm Inc Derivados de n-(1-hidroxi-3-(pirrolidinil)propan-2-il)pirrolidin-3-carboxamida como inhibidores de glucosilceramida sintasa.
CN115322089B (zh) * 2022-07-18 2023-10-03 中国农业科学院烟草研究所(中国烟草总公司青州烟草研究所) 一种覆盆子酮半抗原、人工抗原及其制备方法、抗体和应用

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1555654A (en) 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4065562A (en) 1975-12-29 1977-12-27 Nippon Shinyaku Co., Ltd. Method and composition for reducing blood glucose levels
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
GB2020278B (en) 1978-05-03 1983-02-23 Nippon Shinyaku Co Ltd Moranoline dervitives
JPS568318A (en) 1979-06-28 1981-01-28 Janssen Pharmaceutica Nv Non oral long acting composition of haloperidol and bromperidol derivative
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
EP0144290A3 (de) 1983-12-01 1987-05-27 Ciba-Geigy Ag Substituierte Aethylendiaminderivate
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
ATE197672T1 (de) 1993-08-13 2000-12-15 Seikagaku Kogyo Co Ltd Arzneimittel gegen nervöse erkrankungen
EP0742789B1 (en) 1994-02-02 2000-08-30 The Liposome Company, Inc. Pharmaceutically active compounds and liposomes, and methods of use therof
AU698833B2 (en) 1994-06-10 1998-11-12 Seikagaku Corporation 2-acylaminopropanol compound and medical composition
US5916911A (en) 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
JP2871565B2 (ja) 1995-12-26 1999-03-17 株式会社神戸製鋼所 ローラヘッド押出機とその制御方法
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
AU756008B2 (en) 1998-07-27 2003-01-02 Johns Hopkins University, The Methods for treating conditions modulated by lactosylceramide
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
MXPA02000296A (es) * 1999-07-09 2004-05-21 Univ Michigan Compuestos parecidos a aminoceramida y metodos de uso.
EP1384719A1 (en) 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections
US6407064B2 (en) 1999-12-06 2002-06-18 Seikagaku Corporation Aminoalcohol derivative and medicament comprising the same
JP5009459B2 (ja) 1999-12-06 2012-08-22 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
US6235737B1 (en) 2000-01-25 2001-05-22 Peter Styczynski Reduction of hair growth
PL357674A1 (pl) 2000-04-19 2004-07-26 Thomas Julius Borody Kompozycje i sposoby leczenia zaburzeń związanychz hiperlipidemią
AU2002241724A1 (en) 2000-12-20 2002-07-01 Bristol-Myers Squibb Company Diamines as modulators of chemokine receptor activity
CN100457719C (zh) 2000-12-29 2009-02-04 惠氏公司 区域选择性制备取代的苯并[g]喹啉-3-腈和苯并[g]喹唑啉的方法
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2002062777A2 (en) 2001-01-10 2002-08-15 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
ATE554082T1 (de) 2001-07-16 2012-05-15 Genzyme Corp N-acetylsphingosin glukosyltransferase inhibitor
AU2002348261A1 (en) 2001-11-26 2003-06-10 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
JPWO2003057874A1 (ja) 2001-12-28 2005-05-19 住友製薬株式会社 腎疾患の疾患マーカー及びその利用
CN101001857B (zh) 2002-01-22 2011-06-22 沃尼尔·朗伯有限责任公司 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮
EP1336411A1 (en) 2002-02-14 2003-08-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Compositions and methods for improving enzyme replacement therapy of lysosomal storage diseases
JP2003238410A (ja) 2002-02-21 2003-08-27 Seibutsu Yuki Kagaku Kenkyusho:Kk インスリン抵抗性解除剤
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
GEP20084499B (en) 2002-07-17 2008-10-10 Biogen Idec Inc USE OF INTERFERON-ß FOR TREATMENT OF RENAL FAILURE
JP4575156B2 (ja) 2002-07-17 2010-11-04 アクテリオン ファーマシューティカルズ リミテッド グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体
AU2003225670A1 (en) 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
GB0313678D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
AU2004283631A1 (en) 2003-10-29 2005-05-06 Genzyme Corporation Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
EP1528056A1 (en) 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
JP2007516294A (ja) 2003-12-23 2007-06-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 炎症性の疾患または症状の予防および治療のための方法および組成物
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
JP5154218B2 (ja) 2004-03-16 2013-02-27 ネーデルランドセ オルガニサティエ フォール トエゲパスト−ナトールヴェテンシャッペリク オンデルゾエク ティエヌオー ２型糖尿病、インスリン抵抗性及びメタボリック症候群の治療及び予防においてスフィンゴ脂質を使用する方法
EP1576894A1 (en) 2004-03-16 2005-09-21 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome
ES2375626T3 (es) 2004-05-07 2012-03-02 Merck Patent Gmbh Gm3 sintetasa como diana terapéutica en las complicaciones microvasculares de la diabetes.
ZA200700024B (en) * 2004-05-26 2008-06-25 Fasgen Llc Novel compounds, pharmaceutical compositions containing same, and methods of use for same
US20090111812A1 (en) 2004-06-14 2009-04-30 Musc Foundation For Research Development Methods for treating inflammatory disorders
CN101123879A (zh) 2004-08-20 2008-02-13 约翰·霍普金斯大学 血管新生治疗方法
BRPI0517701A8 (pt) 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
WO2006081273A1 (en) 2005-01-26 2006-08-03 Allergan, Inc. 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroayryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity
WO2007022518A2 (en) 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
WO2008011487A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
WO2008011478A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
EA200901082A1 (ru) 2007-02-09 2010-02-26 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
EP2594563B1 (en) 2007-05-31 2018-07-18 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
CA2701649C (en) 2007-10-05 2016-05-24 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
WO2009117150A2 (en) 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
CN102271678B (zh) 2008-10-03 2017-06-30 简詹姆公司 2‑酰胺基丙醇型葡糖神经酰胺合成酶抑制剂

Also Published As

Publication number Publication date
AU2008307516B2 (en) 2011-11-17
EP2550965A3 (en) 2013-05-15
RU2014102885A (ru) 2015-08-10
US10220039B2 (en) 2019-03-05
US20150216872A1 (en) 2015-08-06
KR20100084647A (ko) 2010-07-27
KR101640263B1 (ko) 2016-07-15
US20100298317A1 (en) 2010-11-25
RU2010117585A (ru) 2011-11-10
MX337396B (es) 2016-03-02
BRPI0817864A2 (pt) 2012-12-25
CN102940627A (zh) 2013-02-27
JP2010540638A (ja) 2010-12-24
JP2014024858A (ja) 2014-02-06
RU2517345C2 (ru) 2014-05-27
MX2010003603A (es) 2010-06-02
WO2009045503A1 (en) 2009-04-09
KR20160085917A (ko) 2016-07-18
SG184721A1 (en) 2012-10-30
BRPI0823522A2 (pt) 2014-01-07
KR20150085139A (ko) 2015-07-22
CA2701649C (en) 2016-05-24
JP2016041761A (ja) 2016-03-31
RU2517345C9 (ru) 2014-08-20
SG10201707161PA (en) 2017-10-30
US8912177B2 (en) 2014-12-16
EP2209473A1 (en) 2010-07-28
JP5896601B2 (ja) 2016-03-30
AU2008307516A1 (en) 2009-04-09
EP2209473B1 (en) 2017-11-22
EP2550965B1 (en) 2019-01-16
EP2550965A2 (en) 2013-01-30
US20170258802A1 (en) 2017-09-14
CN101888840A (zh) 2010-11-17
CA2701649A1 (en) 2009-04-09
ES2660690T3 (es) 2018-03-23
IL204741A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
IL204741A (en) Ceramide History for the Treatment of Multiple Cyst Diseases and Pharmaceuticals Containing These History
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
IL250641B (en) Pharmaceutical preparations for inhibiting nhe-mediated antiport in the treatment of disorders related to fluid retention or salt overload and disorders in the digestive system
IL207546A0 (en) Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
PT1978947E (pt) Derivados nitro-óxido para utilização no tratamento de distrofias musculares
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
EP2007385A4 (en) CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
IL209121A (en) Indazolil history, their medicinal preparations and their use in the preparation of medications for the treatment of inflammatory diseases
IL206080A0 (en) Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
AP2965A (en) Therapeutic compositions and the use thereof
AP2490A (en) Therapeutic compositions and the use thereof
WO2008106102A9 (en) Inhibitors of rtp801 and their use in disease treatment
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
EP1928453A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING RENAL DISEASES
IL194880A (en) Aminazole amine derivatives, their use in the treatment of diseases and pharmaceuticals containing them
IL215840A (en) Arylsulfonamide compounds are converted into two positions 2 and 5, their pharmaceutical composition containing them and their use in the treatment of ccr3-related diseases
IL202307A (en) Multikinase inhibitors for use in the preparation of pharmaceuticals for the treatment of various cancers
IL196606A (en) Use of Eskin for the preparation of medical preparations and medical preparations containing Eskin for the treatment of diseases
EP2056857A4 (en) PHARMACEUTICAL COMPOSITIONS WITH CCL2 AND THEIR USE IN THE TREATMENT OF INFLAMMATION
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
ZA201108106B (en) Use of phthalimide derivatives in the treatment of diseases
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
ZA200707955B (en) Methods and pharmaceutical compositions for the treatment of neurological damage
EP2005964A4 (en) MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF
GB0614365D0 (en) Pharmaceutical compositions and their use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed